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Abstract
Background: Studies from several countries indicate that the incidence and mortality of bloodstream infection (BSI)
have been increasing over time.
Methods: We studied the burden of disease and death related to BSI in a defined geographical area of Mid-Norway,
where BSI episodes were prospectively recorded by the same microbiological department during 12 consecutive years.
Death from BSI was defined as death within 30 days of BSI detection. Age and sex standardized incidence and
mortality rates and case fatality rates were calculated.
Results: Between 2002 and 2013, 1995 episodes of BSI in 1719 patients aged 16 to 99 years were included.
The overall incidence of BSI was 215 per 100,000 person-years. The incidence increased exponentially with
age, particularly in males. The incidence increased from 205 to 223 per 100,000 person-years from 2002–07
to 2008–13. Escherichia coli was the most frequently isolated infective agent, followed by Streptococcus
pneumoniae and Staphylococcus aureus. The rate of S. pneumoniae BSI decreased over time in males (on
average by 9.2% annually), but not in females. The total rate of BSI microbes with acquired resistance
increased slightly over time, but did not exceed 2 episodes per 100,000 person-years. The mortality of BSI
was 32 per 100,000 person-years, higher in males than in females (36 vs. 28 per 100,000 person-years) and
was significantly higher in old age, particularly in males. The total BSI mortality was similar in the first and
second halves of the study period, but the mortality of S. pneumoniae BSI decreased in males (15.0%
annually). The crude case fatality decreased from the first to the second half of the study period (17.2% to
13.1%; p = 0.014). The rate of blood culture sampling increased more than twofold during the study period.
Conclusions: The mortality of BSI remained stable during 2002–2013. At the same time, BSI incidence increased and
case fatality rate decreased, perhaps because an increased rate of blood culture sampling may have led to improved
detection of milder BSI episodes. Very low, yet slightly increasing rates of microbes with acquired resistance were
observed.
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Background
Bloodstream infection (BSI) contributes substantially to
morbidity and mortality worldwide [1]. The annual inci-
dence has been reported between 80 and 257 per 100,000
person-years [2–9]. In Europe, the annual number of BSI
episodes and deaths associated with BSI has been esti-
mated at 1.2 million and 157,000, respectively. The corre-
sponding numbers of hospital-acquired BSIs were found
to be 240,000 episodes and 29,000 deaths [1]. Most studies
report increasing incidence rates [5, 6, 8], but a decreasing
rate has also been described [10].
The burden of BSI includes mortality as well as inci-
dence, but few studies have reported both [1, 3, 6]. Moni-
toring the burden of BSI is important for reasons of
resource allocation and for evaluating prevention and
treatment strategies [11]. As the proportion of elderly
people, more prone to infections, is increasing [12, 13],
knowledge about their burden of severe infections is of
particular importance. Growing antimicrobial resistance
worldwide, associated with increased mortality [14, 15],
make surveillance of BSI microbes and antimicrobial re-
sistance essential. As different prevention and treatment
Table 1 Incidence of bloodstream infection (BSI) stratified by sex in an area of Mid-Norway 2002-2013. Number of episodes and ob-
served and standardized incidence rates, allover and in various subgroups, are shown
Total Females Males


















All BSIs 1995 232 (222–242) 215 961 221 (208–236) 209 1034 242 (228–258) 222
Agee
16–64 years 578 84 (78–92) 82 284 84 (75–94) 83 294 84 (75–95) 82
65–79 years 692 564 (523–607) 555 306 477 (425–534) 473 386 658 (594–727) 646
≥80 years 725 1379 (1280–1483) 1373 371 1122 (1011–1242) 1126 354 1813 (1629–2012) 1826
Place of acquisition
CA-BSI 934 109 (102–116) 102 502 116 (106–126) 110 432 101 (92–111) 94
HCA-BSI 787 91 (85–98) 85 356 82 (74–91) 78 431 101 (92–111) 91
HA-BSI 274 32 (28–36) 30 103 24 (19–29) 23 171 40 (34–47) 37
Infection focus
Urinary tract 752 87 (81–94) 81 429 99 (90–109) 94 323 76 (68–84) 68
Lungs 331 38 (34–43) 36 142 33 (28–39) 31 189 44 (38–51) 41
Biliary tract 220 26 (22–29) 24 93 21 (17–26) 21 127 30 (25–35) 27
Gastrointestinal tract 101 12 (10–14) 11 44 10 (7–14) 9.8 57 13 (10–17) 13
Skin or soft tissue 143 17 (14–20) 16 61 14 (11–18) 13 82 19 (15–24) 18
Other 247 29 (25–33) 27 104 24 (20–29) 23 143 34 (28–39) 31
Unknown 201 23 (20–27) 22 88 20 (16–25) 19 113 26 (22–32) 24
Microbe group
Gram-negative BSI 1133 132 (124–140) 123 616 142 (131–154) 135 517 121 (111–132) 110
Gram-positive BSI 777 90 (84 to 97) 85 310 71 (64–80) 68 467 109 (100–120) 101
Polymicrobial or fungal BSI 85 10 (8–12) 9 35 8 (6–11) 8 50 12 (8–15) 11
Microbes (the four most common)
Escherichia coli 686 80 (74–86) 74 421 97 (88–107) 93 265 62 (55–70) 56
Streptococcuspneumoniae 226 26 (23–30) 25 109 25 (21–30) 24 117 27 (23–33) 25
Staphylococcusaureus 218 25 (22–29) 24 75 17 (14–22) 16 143 34 (28–39) 31
Klebsiella spp. 134 16 (13–18) 14 65 15 (12–19) 14 69 16 (13–20) 15
aBSI episodes per 100,000 person-years (totally 860,630 person-years in individuals ≥16 years, 426, 517 in males, 434,113 in females)
bmales and females standardized to the age distribution of the male and female population of Norway 2010, respectively
cstandardized to the age distribution of females in Norway 2010
dstandardized to the age distribution of males in Norway 2010
ePerson-years in the three age groups were: 16–64 years: males 348,342; females 336,950; 65–79 years: males 58,645; females 64,100; ≥80 years: males 19,530;
females 33,063
Mehl et al. BMC Infectious Diseases  (2017) 17:205 Page 2 of 14
strategies are needed (vaccination programs, antibiotic
regimens, and infection control measures), it is necessary
to separately survey community acquired, health care-
associated, and hospital acquired BSIs [16, 17].
We conducted a prospective study within an area of
Mid-Norway to assess the BSI incidence and mortality,
with emphasis on age and sex differences and time trends.
Methods
As part of the Mid-Norway Sepsis Study we prospectively
recorded episodes of BSI in patients aged 16 years or older
admitted to Levanger Hospital between January 1, 2002
and December 31, 2013. This BSI cohort or parts of it
have previously been used in studies on other aspects of
BSI [18–20], and two studies, describing BSIs with
Staphylococcus aureus 1995–2011 [21] and Streptococcus
pneumoniae 1993–2011 [22], have included the respective
bacterial species from the current cohort. Levanger Hos-
pital is one of two hospitals in Nord-Trøndelag County.
The hospital is an emergency hospital serving the popula-
tion in a defined geographical area of 10 municipalities,
with 68,491 inhabitants aged 16 years and above at the
start of the study, and 75,858 at the end of the study.
Population data of the ten municipalities around Levanger
Hospital for every year between 2002 and 2013, with age
and sex distribution, was obtained from Statistics Norway.
The microbiology laboratory at Levanger Hospital exclu-
sively provided all microbiology services in Nord-Trøndelag
County. Patients hospitalized with BSI were identified and
prospectively registered at the microbiology laboratory. For
each BSI, a registration form was completed by the respon-
sible physician. The main investigator, two subordinate doc-
tors and three research nurses reviewed the patients’
records to verify the data and record additional variables.
Blood cultures were performed in BACTEC 9240 Vacutai-
ner Culture Bottles (Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD) [23], which in 2010 was
replaced by BACTEC FX. The volume of blood drawn was
the same during the study period. A blood culture set con-
sisted of one aerobic and one anaerobic BACTEC bottle
obtained from a single draw. If a second draw was taken
simultaneously from another site, one aerobic bottle was
used. Isolates were identified using standard methods [24].
Antimicrobial susceptibility testing was performed by the
disc diffusion method (Neo-Sensitabs, Rosco Diagnostica,
Taastrup, Denmark). The microbiology laboratory at Levan-
ger Hospital is ISO 15189 accredited.
An episode of BSI was defined by growth of one or
more microbes from blood culture combined with clinical
evidence of systemic infection [25]. A new BSI episode
with the same microbe in the same patient was recorded
if an interval of at least 30 days had passed without signs
of infection since an earlier episode [26]. If more than one
organism was isolated from one or more blood cultures
within a 72-h period, the BSI episode was classified as
polymicrobial. One positive blood culture for organisms
regarded as etiological agents was the requirement for
inclusion. For coagulase-negative staphylococci, alpha-
hemolytic streptococci, or other possible skin contami-
nants, at least two identical isolates from separate
venipunctures were required.
The BSI episodes were classified as hospital-acquired
(HA), health care-associated (HCA) or community ac-
quired (CA) [16, 17]. HA-BSI was diagnosed if the infec-
tion was detected >48 h after admission [27]. Patients who
during the 30 days prior to hospital admission had (1)
been hospitalized two or more days or (2) had received
intravenous therapy or wound care at home or (3)
hemodialysis or chemotherapy at hospital visits or (4)
were nursing home residents, were categorized as having
HCA-BSI. CA-BSI was diagnosed if the infection was de-
tected <48 h after admission and none of the criteria for
HCA-BSI were fulfilled.
We defined death from BSI as death within 30 days of
BSI detection. The patient administrative system at the
hospital receives updated information on vital status from
the national population register, and thus, information on
Fig. 1 Incidence of bloodstream infection (BSI) by place of
acquisition, age, and sex. The figure shows the number of BSI
episodes per 1000 person-years. The number multiplied by 100
gives the rate per 100,000 person-years
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fatal outcome of BSI was complete even if the patient was
discharged from hospital.
A urinary focus was assigned when the same microbe
was isolated from urine and as well as from blood culture
along with clinical signs/symptoms or risk factors for urin-
ary infection, and no other source of infection was identi-
fied. A presumed pulmonary focus was diagnosed with
clinical signs of lower respiratory infection accompanied by
positive radiologic findings. Focus in the biliary tract was
ascertained based on clinical, biochemical and radiological
findings. Signs of infection along with focal growth of the
same microbe as in blood culture were taken as a confirm-
ation of infection in abdomen, skin, soft tissue or other
sites. An unknown focus of infection was assigned when
none of the criteria for ascertaining a focus were met.
Statistical analyses
BSI included both first-time and repeat episodes [6, 7].
The mortality rate was calculated as the total number of
deaths within 30 days of a diagnosis of BSI per 100,000
person-years. Incidence and mortality rates were calcu-
lated for the population between 16 and 99 years. Popula-
tion data during 2002–13 (Statistics Norway), were used
as denominators to calculate age-specific and sex-specific
rates of BSI episodes and BSI related deaths. The inci-
dence rate of HA-BSI was also reported as the number of
patients with HA-BSI in a time period divided by the
number of hospital bed-days in that same time period.
Observed incidence and mortality rates were standardized
to the age and sex distribution of the population of
Norway 2010. Confidence intervals (CIs) of rates were
Number of episodes per 1 000 person-years
       Male             Age          Female






















Skin and subcutaneous tissue 
Other  
Unknown
  Site of infection
Fig. 2 Incidence of bloodstream infection (BSI) by site of infection, age, and sex. Number of BSI episodes per 1000 person-years is
shown. The number multiplied by 100 gives the rate per 100,000 person-years
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calculated based on assumed Poisson distribution. Poisson
regression was used to assess time trends in BSI incidence
and mortality rates (average rate ratio per calendar year),
adjusted for age (in 5-year intervals) and stratified by sex.
The case fatality rate was defined as the total number
of deaths within 30 days of diagnosed BSI episodes di-
vided by the total number of BSI episodes. Confidence
intervals were calculated using Wilson’s approximation
to the binominal distribution [28]. Case fatality rates for
two time periods were compared using chi-square test.
Two-sided p-values <0.05 were considered significant
and 95% confidence intervals (CI) have been reported
where relevant. The analyses were performed using SPSS
22, Stata 13, and StatXact 9.
Results
During the 12-year study period, a total of 1995 episodes
of BSI occurred, 1034 in males and 961 in females,
among 1719 individuals.
Incidence rates allover and by sex and age
The overall incidence rate of BSI (first-time and repeat
episodes) was 215 per 100,000 person-years (Table 1),
and the rate was higher in males than in females (222 vs.
209 per 100,000 person-years). Age-specific BSI rates
were substantially higher in males than in females, par-
ticularly in older age groups (Figs. 1, 2 and 3; Additional
file 1: Table S1). Whereas the incidence was similar for
males and females 16–64 years (82 vs. 83 per 100,000
person- years), males had substantially higher incidence
than females in the age group ≥80 years (1826 vs. 1126
per 100,000 person-years).
Place of acquisition
The rates of CA-, HCA-, and HA-BSI were 102, 85, and
30 per 100,000 person-years, respectively (Table 1).
HCA- and HA-BSIs constituted larger parts of the BSIs
in men than in women, and HCA- and HA-BSI predom-
inated among men in the oldest age groups (Fig. 1). The
total rate of HA-BSI was 38 per 100,000 hospital bed-
days (Additional file 1: Table S2).
Site of infection
The urinary tract was the predominant site of infection
(no. of episodes per 100,000 person-years: 81 overall, 94
in females and 68 in males) (Table 1), followed by the
lungs and the biliary tract. Rates of BSI from the urinary
Fig. 3 Incidence of bloodstream infection (BSI) by main microbe
group, age, and sex. The figure shows the number of BSI episodes
per 1000 person-years. The number multiplied by 100 gives the rate
per 100,000 person-years
Fig. 4 Observed incidence of bloodstream infection (BSI) per
calendar year by different places of acquisition. Number of BSI
episodes per 100,000 person-years is shown
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tract, lungs, and biliary tract were higher in old age, par-
ticularly in males (Fig. 2).
Microbes
Gram-negative BSI was more common in females than
in males (135 vs. 110 per 100,000 person-years) (Table 1),
whereas Gram-positive BSI most often occurred in
males (101 vs. 68 per 100,000 person-years). Escherichia
coli was the most commonly isolated BSI microbe from
all three places of acquisition and predominated in fe-
males (93 vs. 56 per 100,000 person-years) (Table 1).
The second most common microbe was Streptococcus
pneumoniae (25 episodes per 100,000 person-years),
which was evenly distributed between the sexes and
mainly occurred in CA-BSI. Staphylococcus aureus, close
to S. pneumoniae in total rate (24 per 100,000 person-
years), was mostly represented in HCA-BSI and was
significantly more frequent in males than in females (31
vs. 16 episodes per 100,000 person-years).
Time trends in incidence
The observed incidence rate of BSI increased from 190
per 100,000 person-years in 2002 to 257 in 2013 (with a
peak at 278 in 2011) (Fig. 4; Additional file 1: Table S3).
Standardized incidence rates for two time periods, 2002-
2007 and 2008–2013, are shown in Table 2, and age-
adjusted time trends in BSI rate by sex are shown in
Table 3. Overall, the incidence rate increased from 205 to
223 per 100,000 person-years from 2002–07 to 2008–13.
The incidence rate increased on average by 2.8% annually
in females but not significantly in males. HCA-BSIs in-
creased from 72 to 96 per 100,000 person-years from
2002–07 to 2008–13. The HA-BSI rate, calculated as epi-
sodes per 100,000 hospital bed-days, increased from 36 to
40 (Additional file 1: Table S4).
Table 2 Incidence of bloodstream infection (BSI) in two time periods in an area of Mid-Norway. Number of episodes and observed
and standardized incidence rates are shown
2002–2007 2008–2013














All BSIs 921 221(206–235) 205 1074 242 (228–257) 223
Place of acquisition
CA-BSI 471 113 (103–123) 106 463 105 (95–115) 98
HCA-BSI 316 76 (68–84) 72 471 106 (97–116) 96
HA-BSI 134 32 (27–38) 30 140 32 (27–37) 29
Infection focus
Urinary tract 316 76 (68–84) 70 436 98 (89–108) 90
Lungs 169 40 (35–47) 38 162 37 (31–43) 34
Biliary tract 106 25 (21–31) 23 114 26 (21–31) 23
Gastrointestinal tract 47 11 (8–15) 11 54 12 (9–16) 12
Skin or soft tissue 81 19 (15–24) 18 62 14 (11–18) 13
Other 108 25 (21–31) 24 139 31 (26–37) 30
Unknown 94 22 (18–28) 21 107 24 (20–29) 22
Microbe group
Gram-negative BSI 499 119 (109–130) 111 634 143 (132–155) 131
Gram-positive BSI 386 92 (83–102) 87 391 88 (80–97) 81
Polymicrobial or fungal BSI 36 9 (6–12) 8 49 11 (8–15) 10
Microbes (the four most common)c
Escherichia coli 303 73 (65–81) 68 383 86 (78–96) 79
Streptococcus pneumoniae 127 30 (25–36) 29 99 22 (18–27) 21
Staphylococcus aureus 100 24 (19–29 22 118 27 (22–32) 25
Klebsiella spp. 47 11(8–15) 10 88 20 (16–24) 18
aBSI episodes per 100,000 person-years (417,682 person-years in 2002–2007; 442,948 person-years in 2008–2013)
bage and sex standardized to the population of Norway 2010
cless common BSI microbes are listed in Additional file 1: Table S5
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BSIs from the urinary tract increased from 70 to 90 per
100,000 person-years. Gram-negative BSI increased from
111 to 131 per 100,000 person-years, most evident for E.
coli (68 to 79 per 100,000 person-years) and Klebsiella
spp. (10 to 18 per 100,000 person-years). Polymicrobial or
fungal BSI increased from 8 to 10 per 100,000 person-
years, whereas Streptococcus pneumoniae BSI decreased
from 29 to 21 per 100,000 person years. The rate of
Pseudomonas aeruginosa BSI was fairly stable (6.7 to 5.8
per 100,000 person-years), while the rate of candida BSI
increased slightly over time (1.4 to 2.3 in the first and sec-
ond period, respectively) (Additional file 1: Table S5).
BSI microbes with acquired drug resistance
The rate of BSI microbes with acquired drug resistance
(ADR) was very low but it increased slightly over time in
our population (Additional file 1: Table S5). In the first
and second time period, the total rates of ADR microbes
were 0.6 and 2.0 per 100,000 person-years. Methicillin-
resistant S. aureus (MRSA) contributed 0 and 0.2 per
100,000 person-years, penicillin-non-susceptible pneumo-
cocci (PNSP) 0 and 0.4 per 100,000 person-years, and
Enterobacteriaceae producing extended spectrum beta-
lactamase (ESBL-E) 0.6 and 1.4 per 100,000 person-years
in the first and second time period, respectively.
BSI mortality
Death within 30 days occurred in 299 of the BSI episodes,
172 in males and 127 in females. The overall mortality rate
of BSI was 32 per 100,000 person-years (Table 4). The
mortality rate was higher in males than in females (36 vs.
28 per 100,000 person-years) and increased more with age
in males than in females (Fig. 5; Additional file 1: Table
S6). The mortality rate was 35 and 29 per 100,000 person-
years in 2002-07 and 2008-13, respectively (Table 5), but
no significant age-adjusted annual change was observed
(Table 6). Among subgroups of BSI, the mortality rate of
HCA-BSI increased in females (7.4% annually), and the
mortality rate of BSI from the urinary tract increased in
males (11.4% annually). The mortality rate of BSI from
pulmonary infection decreased from 10.4 to 5.7 per
100,000 person-years (annually by 9.0% in males). For
Streptococcus pneumoniae BSI, the mortality rate de-
creased from 4.8 to 1.9 per 100,000 person-years, with an
average annual decrease of 15.0% in males.
Table 3 Age-adjusted time trends in bloodstream infection (BSI) incidence stratified by sex. The table shows BSI rate ratios per
calendar year by Poisson regression
Females Males
BSI rate ratio (95% CI) p-value BSI rate ratio (95% CI) p-value
BSI, allover 1.028 (1.010–1.047) 0.003 1.011(0.993–1.029) 0.22
Place of acquisition
Community acquired 0.998 (0.973–1.024) 0.88 0.976 (0.950–1.004) 0.09
Health care-associated 1.080 (1.047–1.114) <0.001 1.053 (1.024–1.083) <0.001
Hospital acquired 1.009 (0.954–1.067) 0.76 0.999 (0.956–1.043) 0.96
Infection focus
Urinary tract 1.056 (1.027–1.086) <0.001 1.041 (1.008–1.075) 0.013
Lungs 1.021 (0.974–1.071) 0.39 0.969 (0.930–1.010) 0.14
Biliary tract 1.017 (0.959–1.079) 0.57 0.993 (0.944–1.045) 0.80
Gastrointestinal tract 1.017 (0.933–1.108) 0.70 1.052 (0.975–1.136) 0.19
Skin or soft tissue 0.934 (0.868–1.005) 0.069 0.979 (0.920–1.042) 0.51
Other 0.989 (0.935–1.045) 0.69 1.040 (0.991–1.091) 0.11
Unknown 1.043 (0.981–1.109) 0.17 0.987 (0.935–1.041) 0.64
Microbe group
Gram-negative BSI 1.043 (1.019–1.068) <0.001 1.020 (0.995–1.046) 0.12
Gram-positive BSI 0.997 (0.966–1.030) 0.87 0.993 (0.968–1.020) 0.62
Polymicrobial or fungal BSI 1.031 (0.936–1.135) 0.54 1.095 (1.007–1.190) 0.034
Microbes (the four most common)
Escherichia coli 1.044 (1.015–1.073) 0.003 1.002 (0.967–1.037) 0.92
Streptococcus pneumoniae 1.007 (0.954–1.063) 0.80 0.908 (0.860–0.958) <0.001
Staphylococcus aureus 0.988 (0.926–1.055) 0.73 1.032 (0.984–1.082) 0.20
Klebsiella spp. 1.136 (1.053–1.224) 0.001 1.094 (1.020–1.175) 0.012
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Time trends in case fatality
Allover, the case fatality rate decreased from 17.2% to
13.1% (p = 0.014) between 2002–07 and 2008–13, with
similar decreases across the three places of acquisition.
Among the specific infection foci, the case fatality rate
of BSI from pulmonary infection decreased from 28% to
17% (p = 0.026) (Additional file 1: Table S8).
Time trends in blood culture sampling rate
The rate of blood culture sampling increased more than
twofold from 2002 to 2013 (2189 to 4605 blood culture
sets per 100,000 person-years), and the rate of BSI epi-
sodes per 100 blood culture sets decreased from 8.7 in
2002 to 5.6 in 2013 (Additional file 1: Table S3). In the
first (2002–07) and second (2008–13) halves of the study
period, the average rates of blood culture sampling were
3062 and 3977 sets per 100,000 person-years, and the
average rates of BSI episodes per 100 blood culture sets
were 7.2 and 6.1, respectively (Additional file 1: Table S9).
Discussion
The present study provides information on the incidence
and mortality of BSI in an area of Mid-Norway, overall, by
age and sex, by time period, and for specific subgroups of
BSI. The burden of BSI, in terms of both incidence and
mortality, increased strongly with age, particularly in
males. The incidence increased during the 12-year study
period, and the increase was strongest in females, for
HCA-BSI, and for urinary tract and Gram-negative BSIs.
Over the same period, the mortality remained stable and
case fatality rate decreased, possibly because an increased
rate of blood culture sampling may have led to improved
Table 4 Mortality of bloodstream infection (BSI) stratified by sex in an area of Mid-Norway 2002–2013. Number of deaths and observed
and standardized mortality rates, allover and in various subgroups, are shown
Total Females Males
















All BSIs 299 35 (31–39) 32 127 29 (24–35) 28 172 40 (35–47) 36
Place of acquisition
CA-BSI 85 10 (8–12) 9 42 10 (7–13) 9 43 10 (7–14) 9
HCA-BSI 163 19 (16–22) 18 65 15 (12–19) 14 98 23 (19–28) 22
HA-BSI 51 6 (4–8) 6 20 5 (3–7) 4 31 7 (5–10) 7
Infection focus
Urinary tract 63 7 (6–9) 7 31 7 (5–10) 7 32 8 (5–11) 7
Lungs 75 9 (7–11) 8 25 6 (4–9) 6 50 12 (9–15) 11
Biliary tract 15 2 (1–3) 1 4 1 (0–2) 0.4 11 3 (1–5) 2
Gastrointestinal tract 16 2 (1–3) 2 8 2 (0–4) 2 8 2 (0–3) 2
Skin or soft tissue 34 4 (3–6) 4 12 3 (1–5) 3 22 5 (3–8) 5
Other 28 3 (2–5) 3 14 3 (2–5) 3 14 3 (2–5) 3
Unknown 68 8 (6–10) 7 33 8 (5–11) 7 35 8 (6–11) 8
Microbe group
Gram-negative BSI 128 15 (12–18) 14 64 15 (11–19) 14 64 15 (12–19) 14
Gram-positive BSI 144 17 (14–20) 15 48 11 (8–15) 11 96 23 (18–27) 20
Polymicrobial or
fungal BSI
27 3 (2–5) 3 15 3 (2–6) 3 12 3 (1–5) 3
Microbes (the four most common)
Escherichia coli 59 7 (5–9) 6 28 6 (4–9) 6 31 7 (5–10) 6
Streptococcus pneumoniae
31 4 (2–5) 3 10 2 (1–4) 2 21 5 (3–8) 4
Staphylococcus aureus 60 7 (5–9) 6 25 6 (4–9) 5 35 8 (6–11) 7
Klebsiella spp. 20 2 (1–4) 2 12 3 (1–5) 2 8 2 (0.7–4) 2
aDeaths within 30 days of BSI episodes per 100,000 person-years (totally 860,630 person-
years in individuals ≥16 years, 426,517 in males, 434,113 in females)
bmales and females standardized to the age distribution of the male and female population of Norway 2010, respectively
cstandardized to the age distribution of females in Norway 2010
dstandardized to the age distribution of males in Norway 2010
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detection of milder BSI episodes. A shift towards higher
proportions of female sex, Gram-negative etiology, and
urinary tract site may also have influenced the case fatality
rate to some degree. In addition, earlier detection of sepsis
and improved treatment may have had impact. Very low,
yet slightly increasing rates of microbes with acquired re-
sistance were observed.
To our knowledge, this is the first study estimating the
overall burden of BSI in a Norwegian population. Inci-
dence rates of invasive infections with single microbes
have been reported [29–33], but no population-based
study has focused on BSI as a whole. One previous study
described the epidemiology of sepsis in Norway in 1999
[34], and two studies published more than 20 years ago
[26, 35] described BSI incidence and mortality related to
hospital admissions and bed-days, but did not include
population statistics. Strengths of the present study in-
clude the prospective registration of BSIs within a well-
defined source population. All patients with a BSI ac-
quired outside hospital (CA- and HCA-BSI) in our geo-
graphical area were admitted to Levanger Hospital, and
the blood cultures were handled at one microbiology la-
boratory. Some inhabitants in this area will likely have
had BSI during stays at St Olav’s Hospital, the closest
university hospital, so that the true rate of HA-BSI in
our area is slightly higher than is reported in this article.
We did not exclude the very small number of episodes
that occurred in persons who were visitors to the area,
as a similar number of BSIs is likely to have occurred
among inhabitants of our area being on travel elsewhere.
Standardization for the age and sex distribution is repre-
sentative for Norway 2010. Use of international popula-
tion standards could have eased comparison between
studies [36, 37], but most studies in this field have used
regional or national population standards [4, 8, 10].
The comparison of incidence and mortality rates of
BSI between studies is challenging because of differences
in the age groups included and in age- and sex distribu-
tion of populations [37], differences in the classification
of place of acquisition [8, 16, 17, 38], and differences in
the definition of incident episodes: first-time vs. total
number of BSIs, and different time periods since last BSI
required to define a new episode (after 30 days [26],
3 months [6], first episode in another calendar year [36,
37], first episode during the study period [4, 8, 10]). BSI
can affect the same individual several times, and the epi-
sodes are most often independent of each other. To in-
form about the total burden of BSI, we chose to estimate
the total rate of BSI rather than the first-time episodes
only [11]. Compared with our results, incidence rates
(166–189 per 100,000 person-years) [6–8] and mortality
rates (22 per 100,000 person-years) [6] of BSI are some-
what lower in other studies that also included all BSI ep-
isodes. This difference is expected, as these studies also
included children, who are generally at low risk of BSI.
An increase in BSI incidence over time have also been
reported in Finland (from 147 to 168 per 100,000
person-years from 2004 to 2007) [6] and in Northern
Denmark (from 120 to 201 per 100,000 person-years
from 1992 to 2006) [8], although a study from Funen,
Denmark, [10] of first-time BSI among people ≥16 years
of age reported a decrease in BSI incidence from 254 to
199 per 100,000 person-years through 2000 to 2008.
Similar to our findings, the increase in BSI incidence
was accompanied by a decreasing case fatality rate in
Denmark (22.7% to 20.6%) [8], but not in Finland (12.6%
to 13.2%) [6]. At the same time, we observed a relatively
stable mortality rate of BSI, as has also been reported in
Finland [6]. The combination of increased incidence, re-
duced case fatality, and stable mortality may be ex-
plained by improvements in the detection of milder, less
fatal BSI episodes. In support of that explanation, we
and others (5, 10) have observed increasing rates of
blood culture sampling over time, and the number of
BSI episodes per 100 blood culture sets decreased with
time in our study as was found in Funen, Denmark [10],
though not in Northern Denmark or in Finland [5, 8].
Fig. 5 Mortality of bloodstream infection (BSI) by main microbe group,
age, and sex. The figure shows number of deaths within 30 days of BSI
episodes per 1000 person-years. The number multiplied by 100 gives
the rate per 100,000 person-years
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Alternatively, the true mortality rate of BSI may have de-
creased, but the higher detection rate of BSIs may have
led to more deaths being attributed to BSI, thus masking
a true decline in mortality. In 2007, we updated our local
recommendations on sepsis diagnosis and treatment,
based on the guidelines of the international Surviving
Sepsis Campaign [39], and we performed regular teach-
ing sessions about sepsis for physicians and nurses and
implemented standardized observation of patients with
suspected sepsis at the wards. Earlier detection and
treatment may have improved survival of BSI towards
the end of the study period. An in-depth discussion of
case fatality rate in the present BSI cohort is given else-
where [18–22].
The high incidence and mortality of BSI in the older
ages in our study, particularly in men, corresponds to
what has also been reported by others [4, 6, 40, 41].
While the absolute number of BSIs decreased beyond
85 years, the population beyond this age is progressively
smaller and the incidence continued to increase. As the
proportion of older people will rise in our part of the
world in the decades to come [12, 13], the challenges as-
sociated with BSI will escalate.
Compared to our results, HA-BSI accounted for a
higher proportion of BSIs (15–58%) in most recent pub-
lications, whereas CA-BSI accounted for a lower propor-
tion (18–44%) [1, 42]. An increasing rate of HCA-BSI
with time, similar to our results, was also recently re-
ported from Denmark [8], whereas another Danish study
found no change with time in HCA-BSI, though re-
ported decreasing incidence rates for both CA-BSI and
HA-BSI [10]. In the present study as well as in a Finnish
study [6], Gram-negative BSI was most frequent in fe-
males whereas Gram-positive BSI predominated in
males. During the study period, Gram-negative BSIs in-
creased whereas Gram-positive BSIs decreased. Similar
trends were found in Australia [43]. In Finland, however,
both Gram-positive and Gram-negative BSIs increased
Table 5 Mortality of bloodstream infection (BSI) in two time periods in an area of Mid-Norway. Number of deaths and observed and
standardized mortality rates are shown
2002–2007 2008–2013












All BSIs 158 37 (32–44) 35 141 32 (17–53) 29
Place of acquisition
CA-BSI 50 12 (9–16) 11.0 35 7.9 (5.5–11.0) 7.1
HCA-BSI 77 18 (15–23) 17.0 86 19 (16–24) 17.3
HA-BSI 31 7 (5–11) 7.0 20 4.5 (2.8–7.0) 4.1
Infection focus
Urinary tract 28 7 (4–10) 6.2 35 7.9 (5.5–11.0) 7.0
Lungs 47 11 (8–15) 10.4 28 6.3 (4.2–9.1) 5.7
Biliary tract 7 1.7 (0.7–3.5) 1.6 8 1.8 (0.78–3.6) 1.5
Gastrointestinal tract 11 2.6 (1.2–4.7) 2.4 5 1.1 (0.37–2.6) 1.0
Skin or soft tissue 16 3.8 (2.2–6.2) 3.5 18 4.1 (2.4–6.4) 3.7
Other 14 3.4 (1.8–5.6) 3.0 14 3.2 (1.7–5.3) 2.9
Unknown 35 8 (6–12) 7.8 33 7.5 (5.1–10.4) 6.8
Microbe group
Gram-negative BSI 64 15 (12–20) 14.4 64 14 (11–18) 13.0
Gram-positive BSI 81 19 (15–24) 17.9 63 14 (11–18) 12.7
Polymicrobial or fungal BSI 13 3.1 (1.7–5.3) 2.8 14 3.2 (1.7–5.3) 2.8
Microbes (the four most common)c
Escherichia coli 31 7 (5–11) 7.1 28 6.3 (4.2–9.1) 5.7
Streptococcus pneumoniae 22 5 (3–8) 4.8 9 2.1 (0.9–3.8) 1.9
Staphylococcus aureus 30 7 (5–10) 6.7 30 7 (5–10) 6.1
Klebsiella spp. 8 1.7 (0.7–3.5) 1.6 12 2.7 (1.4–4.7) 2.4
aDeath within 30 days of BSI episodes per 100,000 person-years (417,682 person-years in 2002–2007; 442,948 person-years in 2008–2013)
bage and sex standardized to the population of Norway 2010
cmortality in BSI episodes with less common microbes is shown in Additional file 1: Table S7
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during 2004–2007 [6]. In most other BSI studies as well
as in the present study, [4, 8, 11, 38, 44] E. coli, S. pneu-
moniae, and S. aureus were the three most commonly
occurring BSI microbes, accounting for more than one-
half of all BSI episodes. The incidence rate of E. coli was
higher in our study than in other studies (43 per 100,000
person-years reported both from Finland [6] and Eng-
land [7]), which, however, also included children. One
Danish study [10] found a decreasing incidence rate of
E. coli (70 to 57 per 100,000 person-years). However, an-
other Danish study [8] reported an increasing rate of E.
coli and reported increased rates of BSI from the urinary
tract, similar to the pattern observed by us.
A decreasing occurrence [11, 45–48] and mortality
[47] of S. pneumoniae is reported in Norway and other
countries after the introduction of pneumococcal
conjugate vaccines. In Norway, the vaccine was
implemented in the immunization program for children
in 2006. However, a reduced occurrence of invasive
pneumococcal infection is seen also among adults and
even among elderly people, due to a herd effect [11, 47].
Furthermore, pneumococcal vaccine is recommended
for people >65 years and for those who have undergone
an invasive pneumococcal infection. Noteworthy, the
decreased rate of S. pneumoniae BSI in our study was
observed in males but not in females. A possible explan-
ation of this sex difference may be differences in
smoking habits, which is a risk factor for invasive
pneumococcal disease [49]. The peak prevalence of
smoking in Norwegian males occurred 20 years earlier
than in females, whose peak prevalence cohort is now
in the age group 65–79 years [50].
The incidence of S. aureus BSI in our study was similar
to a recent study from an area of South-East Norway (27.6
per 100,000 person-years) [32]. The present study as well as
others [6, 32] found a higher rate of S. aureus BSI in males
than in females. The large proportion of HCA infections
among the S. aureus BSIs was also described in a previous
report from our catchment area [21]. Klebsiella spp.
showed a higher and more increasing (10 to 18 per 100,000
person-years) incidence rate in our study than was found in
a Canadian study (7 per 100,000 during 2000–2007) [51]. A
nationwide study of invasive Pseudomonas aeruginosa in-
fection in Norway 1999–2002 found an incidence rate of
3.2 per 100,000 person-years [31], which was lower than
was found in the present study. The incidence rate of
Table 6 Age-adjusted time trends in bloodstream infection (BSI) mortality stratified by sex. BSI rate ratios per calendar year by
Poisson regression are shown
Females Males
Mortality rate ratio (95% CI) p-value Mortality rate ratio (95% CI) p-value
BSI, all 1.014 (0 .965–1.067) 0.58 0.974 (0.933–1.017) 0.23
Place of acquisition
Community acquired 0.917 (0.838–1.002) 0.056 0.979 (0.8980–1.068) 0.64
Health care-associated 1.074 (0.999–1.154) 0.052 0.982 (0.928–1.039) 0.53
Hospital acquired 0.998 (0.882–1.129) 0.97 0.915 (0.825–1.015) 0.095
Infection focus
Urinary tract 0.989 (0.893–1.095) 0.83 1.114 (1.001–1.239) 0.047
Lungs 1.018 (0.908–1.140) 0.76 0.910 (0.838–0.988) 0.024
Biliary tract 0.982 (0.740–1.303) 0.90 1.030 (0.867–1.226) 0.73
Gastrointestinal tract 0.978 (0.800–1.195) 0.83 0.891 (0.724–1.097) 0.28
Skin or soft tissue 1.007 (0.855–1.186) 0.93 0.994 (0.880–1.122) 0.92
Other 0.913 (0.782–1.065) 0.25 1.024 (0.879–1.193) 0.76
Unknown 1.086 (0.981–1.202) 0.11 0.922 (0.836–1.017) 0.10
Microbe group
Gram-negative BSI 1.023 (0.953–1.098) 0.53 1.011 (0.941–1.085) 0.77
Gram-positive BSI 0.999 (0.921–1.084) 0.99 0.937 (0.884–0.993) 0.027
Polymicrobial or fungal BSI 0.952 (0.829–1.093) 0.49 1.072 (0.911–1.260) 0.40
Microbes (the four most common)
Escherichia coli 1.014 (0.911–1.129) 0.79 0.957 (0.964–1.060) 0.40
Streptococcus pneumoniae 0.971 (0.812–1.161) 0.75 0.850 (0.745–0.971) 0.017
Staphylococcus aureus 0.985 (0.880–1.103) 0.80 0.972 (0.882–1.070) 0.56
Klebsiella spp. 1.169 (0.960–1.425) 0.12 1.107 (0.916–1.338) 0.29
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candida BSI in our study was slightly lower than what was
found in a nationwide study from Norway 2004–2012 (3.9
per 100,000 person-years) [30].
The incidence rate of MRSA in our study was similar to
what was found in Copenhagen, Finland, and Western
Sweden 2005–08 (<1 per 100,000 person-years) [36], and
much lower than what was found in Canada and Australia
2005–08 (7.4 and 4.9 per 100,000 person-years) [36] and in
the US and the UK 2006–08 (22 and 3.5 per 100,000
person-years) [52]. Even though ESBL-E has been a rapidly
increasing challenge the last 15 years [53, 54], population-
based incidence rates for ESBL-E are, so far, not commonly
reported. Two Canadian studies found substantially higher
and more increasing rates of community onset infections
with ESBL-producing microbes (5.5 per 100,000 person-
years in 2000–2002 [55], 10.6 per 100,000 person-years
some years later [53]) than in the present study.
Conclusions
Overall, both the incidence and the mortality rates of BSI
increased significantly by age, particularly in males. As the
proportion of older people increases, geriatric BSIs will be
an escalating challenge. The rate of BSI episodes increased
through the study period, but the mortality rate was mainly
unchanged, and the case fatality rate decreased. A more
than twofold increase in the rate of BSI sampling may have
contributed to the detection of milder and ultimately less
fatal episodes and a shift towards higher proportions of fe-
male sex, Gram-negative etiology, and urinary tract site,
but earlier detection and improved treatment may have had
impact. In pneumococcal BSI, the incidence as well as the
mortality decreased in males but not in females. Pneumo-
coccal vaccine probably has contributed, and the difference
between sexes is possibly due to sex-specific changes in
smoking habits. We observed very low yet slightly increas-
ing rates of microbes with acquired resistance.
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